D’Ascanio, A. M., Mullally, J. A., & Frishman, W. H. (2024). Cagrilintide: A long-acting amylin analog for the treatment of obesity. Cardiology in Review, 32(1), 83–90. https://doi.org/10.1097/CRD.0000000000000513

Kruse, T., Hansen, J. L., Dahl, K., Schäffer, L., Sensfuss, U., Poulsen, C., Schlein, M., Hansen, A. M. K., Jeppesen, C. B., de la Cour, C. D., Clausen, T. R., Johansson, E., Fulle, S., Skyggebjerg, R. B., & Raun, K. (2021). Development of cagrilintide, a long acting amylin analogue. Journal of Medicinal Chemistry, 64(17), 11183–11194. https://doi.org/10.1021/acs.jmedchem.1c00565

Cao, J., Belousoff, M. J., Johnson, R. M., Keov, P., Mariam, Z., Deganutti, G., Christopoulos, G., Hick, C. A., Reedtz-Runge, S., Glendorf, T., Ballarín-González, B., Raun, K., Bayly-Jones, C., Wootten, D., & Sexton, P. M. (2025). Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nature Communications, 16, Article 3389. https://doi.org/10.1038/s41467-025-58680-y